A few of the first Risperdal lawsuits filed over breast growth side effects in males are set to go to trial soon in Pennsylvania state court. The start date of the first Risperdal bellwether trial was recently delayed until November 3, 2014, and the second trial is expected to begin in February 2015. This small group of Risperdal complaints will be heard before the Philadelphia Court of Common Pleas, and represents allegations raised in hundreds of other lawsuits filed against Johnson & Johnson over Risperdal breast growth side effects. If you believe you have been adversely affected by side effects of Risperdal, contact a knowledgeable Risperdal attorney today to explore your possible compensation options.
09 Oct 2014
According to the findings of an important new report, doctors may only follow recommended guidelines for prescribing controversial antipsychotic drugs like Risperdal to children about half of the time. Late last month, the Vermont State Legislature’s Mental Health Oversight Committee held a hearing on physician practices in Vermont, focusing on the prescription of powerful antipsychotic medications among children. During the hearing, the Director of the Pediatric Psychiatry Clinic at the University of Vermont’s College of Medicine, Dr. David C. Rettew, noted that, while rates of antipsychotic prescriptions among children were dropping in Vermont, doctors were found to follow prescribing guidelines established by the American Academy of Child and Adolescent Psychiatry (AACAP) only about 51% of the time.
A group of federal regulators, elder care advocates, professional organizations and families have joined together in an effort to limit the unnecessary use of potentially dangerous antipsychotic drugs among elderly residents in nursing home facilities nationwide. According to reports, antipsychotic drugs like Risperdal are commonly used in nursing homes across the country as a form of chemical restraint, intended to drug elderly patients and make them easier to control. In many cases, these elderly patients suffer from dementia, and a growing body of research has indicated that Risperdal and similar antipsychotic drugs may pose a serious risk of injury or death among dementia patients, while providing little to no benefit.